Sabrient Small Cap Growth, 21 (Terminated)   Ticker: FWRYZX
 
 Trust Performance  (as of 3/23/2020) *Inception Date is 12/21/2018 
  Cumulative Total Return Average Annual Total Return
  YTD Since
Inception*		 3 mo 6 mo 1 yr 3 yr 5 yr 10 yr Since
Inception*
Distributions Reinvested
With Transactional
Sales Charge		 -52.48%  -38.71%  -52.53%  -49.11%  -47.31%  N/A  N/A  N/A  -32.30% 
Without Transactional
Sales Charge		 -52.48%  -37.87%  -52.53%  -48.42%  -46.59%  N/A  N/A  N/A  -31.56% 
Distributions Received in Cash
With Transactional
Sales Charge		 -52.48%  -38.22%  -52.53%  -48.71%  -46.89%  N/A  N/A  N/A  -31.87% 
Without Transactional
Sales Charge		 -52.48%  -37.37%  -52.53%  -48.01%  -46.16%  N/A  N/A  N/A  -31.13% 
 
S&P SMALL CAP 600 GROWTH TR (SPTRSG) -37.88%  -21.20%  -38.04%  -33.89%  -30.59%  N/A  N/A  N/A  -17.29% 


 Performance Calculator
 From Date: 
To Date: 
  Cumulative
Total Return		 Average Annual
Total Return
With Transactional Sales Charge (Distributions Reinvested) -38.71%    -32.30%   
Without Transactional Sales Charge (Distributions Reinvested) -37.87%    -31.56%   
With Transactional Sales Charge (Distributions Received in Cash) -38.22%    -31.87%   
Without Transactional Sales Charge (Distributions Received in Cash) -37.37%    -31.13%   
S&P SMALL CAP 600 GROWTH TR (SPTRSG) -21.20%    -17.29%   


Sales Charges (based on a $10 public offering price)
Standard Accounts
Transactional Sales Charges: Initial: 0.00%
  Deferred: 1.35%
Creation & Development Fee:   0.50%
Maximum Sales Charge:   1.85%
 
Fee/Wrap Accounts
Creation & Development Fee: 0.50%
Maximum Sales Charge: 0.50%
The table above shows the initial offering period sales charge. Certain performance periods shown on this page may begin after the end of the initial offering period and reflect a secondary market sales charge. Please see the prospectus for sales charge details, including the secondary market sales charge amount applicable to a period.

Past Performance is no indication of future results. Investment returns and principal value will fluctuate and units when sold or redeemed, may be worth more or less than their original cost. All returns are historical and do not represent potential future performance. This report is not and should not be construed as an offer to buy or sell securities.

Unless an index is indicated to be a price only index, all index returns assume that dividends are reinvested when they are received.

Returns With Transactional Sales Charge reflect the maximum transactional sales charge that would be payable by an investor upon sale or redemption of units at the end of the applicable period(s). The transactional sales charge includes any initial or deferred sales charges other than the creation and development fee. These returns do not reflect any creation and development fee prior to collection (generally the close of the initial offering period). Any creation and development fee is reflected in the returns as of the time of payment by a trust.

Returns Without Transactional Sales Charge do not reflect any transactional sales charge and do not reflect any creation and development fee prior to collection (generally the close of the initial offering period). Any creation and development fee is reflected in the returns as of the time of payment by a trust.

If applicable, returns shown with distributions reinvested assume distributions are reinvested on the reinvestment date.

Risk Considerations

Equity Risk. An investment in a portfolio containing common stocks is subject to certain risks, such as an economic recession and the possible deterioration of either the financial condition of the issuers of the equity securities or the general condition of the stock market.

Sector Concentration Risk. A portfolio which is concentrated in an individual sector is subject to additional risks, including limited diversification.

COVID-19 Economic Impact Risk. The ongoing effects of the COVID-19 global pandemic, or the potential impacts of any future public health crisis, may cause significant volatility and uncertainty in global financial markets. While vaccines have been developed, there is no guarantee that vaccines will be effective against future variants of the disease.

Financials Risk. The companies engaged in the financials sector are subject to the adverse effects of volatile interest rates, economic recession, decreases in the availability of capital, increased competition from new entrants in the field, and potential increased regulation.

Foreign Securities Risk. Securities of non-U.S. issuers are subject to additional risks, including currency fluctuations, political risks, withholding, the lack of adequate financial information, and exchange control restrictions impacting non-U.S. issuers.

Industrials Risk. The companies engaged in the industrials sector are subject to a deterioration in the general state of the economy, intense competition, domestic and international politics, excess capacity and changing spending trends.

REITs Risk. An investment in a portfolio containing REIT securities is subject to additional risks including limited diversification. Companies involved in the real estate industry are subject to changes in the real estate market, vacancy rates and competition, volatile interest rates and economic recession.

Small-Cap and Mid-Cap Risk. An investment in a portfolio containing small-cap and mid-cap companies is subject to additional risks, as the share prices of small-cap companies and certain mid-cap companies are often more volatile than those of larger companies due to several factors, including limited trading volumes, products, financial resources, management inexperience and less publicly available information.

Volatility Risk. The value of the securities held by the trust may be subject to steep declines or increased volatility due to changes in performance or perception of the issuers.

Operational Risk. As the use of Internet technology has become more prevalent in the course of business, the trust has become more susceptible to potential operational risks through breaches in cybersecurity.

This product information does not constitute an offer to sell, or a solicitation of an offer to buy securities in any state to any person to whom it is not lawful to make such an offer. Sales of any of these securities must include prospectus delivery and the services of a retail broker/dealer duly licensed in the appropriate states.

Not FDIC Insured, Not Bank Guaranteed and May Lose Value.

CUSIP identifiers have been provided by CUSIP Global Services, managed on behalf of the American Bankers Association by FactSet Research Systems Inc. and are not for use or dissemination in a manner that would serve as a substitute for any CUSIP service. The CUSIP Database, ©2024 CUSIP Global Services. "CUSIP" is a registered trademark of the American Bankers Association.